Bonus BioGroup Ltd.
Tel Aviv Stock Exchange BONS.TA
Bonus BioGroup Ltd. Net Income for the year ending December 31, 2023: USD -7.86 M
-
Bonus BioGroup Ltd. Net Income for the year ending December 31, 2022 was USD -11.00 M, a 62.06% change year over year.
-
Bonus BioGroup Ltd. Net Income for the year ending December 31, 2021 was USD -28.99 M, a -323.25% change year over year.
-
Bonus BioGroup Ltd. Net Income for the year ending December 31, 2020 was USD -6.85 M, a -6.54% change year over year.
-
Bonus BioGroup Ltd. Net Income for the year ending December 31, 2019 was USD -6.43 M, a -28.44% change year over year.
| Date | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) | Net Income Margin |
|---|
| CEO | Dr. Shai Meretzki Ph.D. |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | Matam Advanced Technology Park |
| Employees | 58 |
| Sector | Health Care |
| Industries | |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email